|
⚲
|
| Keyboard |
| Invus Public Equities LP
✚
|
|
|---|---|
| CIK # | 0001340097 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001340097] | |
| 4 | [0001340097] | |
| SC 13G | [0001340097] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Invus Public Equities LP | SQZ Biotechnologies Co | [2020-11-13] |
| Invus Public Equities LP | Proqr Therapeutics NV | [2018-02-09] |
| Invus Public Equities LP | Proqr Therapeutics NV | [2017-07-06] |
| Invus Public Equities LP | Sophiris Bio Inc | [2013-08-27] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-12-10 | Sell | 1,600,000 | $41.65 | 66,640,000 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-11-25 | Sell | 208,272 | $37.63 | 7,837,275 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-11-25 | Sell | 43,887 | $38.43 | 1,686,577 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-11-25 | Sell | 126,442 | $39.51 | 4,995,723 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-11-25 | Sell | 149 | $40.98 | 6,106 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2024-11-25 | Sell | 30,683 | $40.14 | 1,231,616 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-08 | Sell | 260,873 | $0.19 | 49,566 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-07 | Sell | 61,488 | $0.18 | 11,068 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-06 | Sell | 55,732 | $0.18 | 10,032 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-05 | Sell | 164,523 | $0.19 | 31,259 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-02 | Sell | 286,200 | $0.20 | 57,240 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-08-01 | Sell | 63,564 | $0.22 | 13,984 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-07-30 | Sell | 756,835 | $0.22 | 166,504 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-07-29 | Sell | 363,949 | $0.24 | 87,348 |
|
Crescent Biopharma Inc GLYC
Common Stock
|
2024-07-26 | Sell | 258,335 | $0.24 | 62,000 |
|
Lexicon Pharmaceuticals Inc LXRX
Series A Convertible Preferred Stock · derivative
|
2024-05-10 | Grant | 1,150,922 | $108.50 | 124,875,037 |
|
Lexicon Pharmaceuticals Inc LXRX
Common Stock
|
2024-05-10 | Option exercise | 57,546,100 | ||
|
Lexicon Pharmaceuticals Inc LXRX
Series A Convertible Preferred Stock · derivative
|
2024-05-10 | Option exercise | 1,150,922 | $0.00 | |
|
Lexicon Pharmaceuticals Inc LXRX
Series A Convertible Preferred Stock
|
2024-03-13 | Grant | 1,150,922 | $108.50 | 124,875,037 |
|
Scholar Rock Holding Corp SRRK
Common Stock
|
2023-10-12 | Buy | 2,189,781 | $6.85 | 15,000,000 |
| showing 20 of 89 most recent transactions | |||||